Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chiang J Li

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Cell Cycle (Georgetown, Tex.)|June 27, 2012
Induction of cancer cell stemness by chemotherapyXingwang Hu, Laura Ghisolfi, Andrew C Keates, et al.
Cell Cycle (Georgetown, Tex.)|September 14, 2006
Selective induction of necrotic cell death in cancer cells by beta-lapachone through activation of DNA damage response pathwayXiangao Sun, Youzhi Li, Wei Li, et al.
Molecules and Cells|April 9, 2013
RNA interference-mediated simultaneous silencing of four genes using cross-shaped RNATae Yeon Lee, Chan Il Chang, Dooyoung Lee, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 22, 2015
Suppression of cancer relapse and metastasis by inhibiting cancer stemnessYouzhi Li, Harry A Rogoff, Sarah Keates, et al.
Molecular Cancer Therapeutics|May 21, 2010
ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activityNeru Munshi, Sébastien Jeay, Youzhi Li, et al.
The Journal of Gene Medicine|January 10, 2012
Enhanced intracellular delivery and multi-target gene silencing triggered by tripodal RNA structuresChan Il Chang, Tae Yeon Lee, Sera Kim, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 22, 2009
Asymmetric shorter-duplex siRNA structures trigger efficient gene silencing with reduced nonspecific effectsChan Il Chang, Jae Wook Yoo, Sun Woo Hong, et al.
Cancer Immunology, Immunotherapy : CII|June 21, 2015
TLR7 tolerance is independent of the type I IFN pathway and leads to loss of anti-tumor efficacy in miceErina Koga-Yamakawa, Masashi Murata, Simon J Dovedi, et al.
The Lancet. Gastroenterology & Hepatology|February 5, 2018
Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trialDerek J Jonker, Louise Nott, Takayuki Yoshino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2022
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction AdenocarcinomaManish A Shah, Kohei Shitara, Florian Lordick, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Cell Cycle (Georgetown, Tex.)|June 27, 2012
Induction of cancer cell stemness by chemotherapyXingwang Hu, Laura Ghisolfi, Andrew C Keates, et al.
Cell Cycle (Georgetown, Tex.)|September 14, 2006
Selective induction of necrotic cell death in cancer cells by beta-lapachone through activation of DNA damage response pathwayXiangao Sun, Youzhi Li, Wei Li, et al.
Molecules and Cells|April 9, 2013
RNA interference-mediated simultaneous silencing of four genes using cross-shaped RNATae Yeon Lee, Chan Il Chang, Dooyoung Lee, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 22, 2015
Suppression of cancer relapse and metastasis by inhibiting cancer stemnessYouzhi Li, Harry A Rogoff, Sarah Keates, et al.
Molecular Cancer Therapeutics|May 21, 2010
ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activityNeru Munshi, Sébastien Jeay, Youzhi Li, et al.
The Journal of Gene Medicine|January 10, 2012
Enhanced intracellular delivery and multi-target gene silencing triggered by tripodal RNA structuresChan Il Chang, Tae Yeon Lee, Sera Kim, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 22, 2009
Asymmetric shorter-duplex siRNA structures trigger efficient gene silencing with reduced nonspecific effectsChan Il Chang, Jae Wook Yoo, Sun Woo Hong, et al.
Cancer Immunology, Immunotherapy : CII|June 21, 2015
TLR7 tolerance is independent of the type I IFN pathway and leads to loss of anti-tumor efficacy in miceErina Koga-Yamakawa, Masashi Murata, Simon J Dovedi, et al.
The Lancet. Gastroenterology & Hepatology|February 5, 2018
Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trialDerek J Jonker, Louise Nott, Takayuki Yoshino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2022
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction AdenocarcinomaManish A Shah, Kohei Shitara, Florian Lordick, et al.
Pageof 3